Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | ZKAB001 |
Indication/Tumor Type | osteosarcoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | osteosarcoma | predicted - sensitive | ZKAB001 | Case Reports/Case Series | Actionable | In a Phase I/II trial, ZKAB001 treatment resulted in improved 6, 12, and 24-month event-free survival (100%) in osteosarcoma patients with CD274 (PD-L1) expression (TPS >/= 1%) compared to a 6-month EFS of 84.5% and 12 and 24-month EFS of 64.7% in patients without CD274 (PD-L1) expression (PMID: 36469563). | 36469563 |
PubMed Id | Reference Title | Details |
---|---|---|
(36469563) | First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. | Full reference... |